Recent Updates
Recently added Catalysts
ANRO Negative Sentiment Score: 25/100

Alto Neuroscience, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before September 19, 2025 to Discuss Your Rights – ANRO

Key Takeaway: Alto Neuroscience, Inc. is currently involved in a class action securities lawsuit filed by Levi & Korsinsky, which seeks to recover losses for investors affected by alleged securities fraud. The complaint contends that the company made false statements regarding the effectiveness of its product pipeline, particularly ALTO-100, in treating major depressive disorder. It further claims that the clinical and commercial prospects of ALTO-100 were exaggerated, leading to materially misleading public statements about the company's financial health. Investors have until September 19, 2025, to seek appointment as lead plaintiff in the case.

Market Sentiment Analysis

CONCERNS & RISKS

  • Alto Neuroscience is facing a class action lawsuit for alleged securities fraud.
  • The lawsuit claims that the company's product, ALTO-100, was less effective than communicated.
  • There are allegations that the company's financial and business prospects were misleadingly overstated.

Full Press Release Details

NEW YORK, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Alto Neuroscience, Inc. ("Alto Neuroscience, Inc." or the "Company") (NYSE: ANRO) of a class action securities lawsuit.
CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Alto Neuroscience, Inc. investors who were adversely affected by alleged securities fraud. This lawsuit is on behalf of a class consisting of all persons and entities that purchased or otherwise acquired: (a) Alto common stock pursuant and/or traceable to the Offering Documents issued in connection with the Company’s initial public offering conducted on or about February 2, 2024; and/or (b) Alto securities between February 2, 2024 and October 22, 2024, both dates inclusive. Follow the link below to get more information and be contacted by a member of our team:
ANRO investors may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.
CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (i) The Company’s product pipeline, ALTO-100, was less effective in treating major depressive disorder than defendants had led investors to believe; (ii) accordingly, ALTO-100’s clinical, regulatory, and commercial prospects were overstated; (iii) as a result, Alto’s business and/or financial prospects were overstated; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.
WHAT'S NEXT? If you suffered a loss in Alto Neuroscience, Inc. during the relevant time frame, you have until September 19, 2025 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate.
WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
33 Whitehall Street, 17th Floor

Tags

Frequently Asked Questions

What is the Alto Neuroscience class action lawsuit about?

It seeks to recover losses for investors due to alleged securities fraud affecting Alto Neuroscience.

Who can participate in the lawsuit against Alto Neuroscience?

All individuals and entities that purchased Alto common stock between February 2 and October 22, 2024, may participate.

What are the allegations in the Alto Neuroscience case?

The lawsuit claims false statements about the effectiveness of ALTO-100 and overstated business prospects.

Is there any cost to participate in the lawsuit?

No, class members may be entitled to compensation with no out-of-pocket costs.

What is the deadline to join the Alto Neuroscience lawsuit?

Investors have until September 19, 2025, to request lead plaintiff status.

Last updated: Sep 5, 2025